Work

Comparative effectiveness of obesity treatments after initial therapy with semaglutide or tirzepatide: a target trial emulation using data from Cleveland Clinic electronic health records

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Comparative effectiveness data on alternative obesity treatments after initial semaglutide or tirzepatide therapy are lacking. Methods We conducted a target trial emulation [TTE] using observational data from Cleveland Clinic electronic health records in Ohio and Florida, USA, including linked pharmacy dispensation data, from January 1, 2021, to December 31, 2025, to compare alternative obesity treatments after initial semaglutide or tirzepatide therapy. At TTE enrollment, treatment strategies were continuation of the original medication, switching between semaglutide and tirzepatide, switching to another obesity medication [OM], undergoing metabolic and bariatric surgery [MBS], or discontinuation (defined by a supply gap >90 days). Outcomes were changes in body weight, glycated hemoglobin in patients with type 2 diabetes, and systolic blood pressure in patients with hypertension, measured from the initial semaglutide or tirzepatide fill to 1 and 2 years after TTE enrollment. Inverse probability of treatment, per protocol censoring, and observation weights were used to account for confounding and selection bias. Findings Among 20,486 patients (mean [SD] age, 56.7 [12.6] years; 12,915 [63.0%] female, mean [SD] BMI, 38.0 [7.7]), weight change from initial fill of semaglutide or tirzepatide fill to 2 years post TTE enrollment was −10.9% (95% CI, −13.1 to −9.1) with continued original medication, −16.0% (−19.4 to −12.3) with switching between semaglutide and tirzepatide, −8.2% (−12.7 to −3.0) with switching to another OM, −28.2% (−36.8 to −19.6) with undergoing MBS, and −4.0% (−6.3 to −1.0) with discontinuation, based on per-protocol analysis. Among 15,154 patients originally on semaglutide, switching to tirzepatide produced greater weight reduction than continuing semaglutide (difference of 3.0 kg, 95% CI, 1.2–5.0), whereas among 5332 patients originally on tirzepatide, continuing the original medication produced greater weight loss than switching to semaglutide (difference of 4.5 kg, 95% CI, 0.1–7.3). Changes in HbA1c and SBP largely followed the same pattern. Interpretation Our findings highlight the importance of continued obesity management and warrant further investigation in diverse populations and real-world clinical settings. These results could inform future research and support patient-clinician discussions about alternative therapy options in patients who consider switching or stopping injectable semaglutide or tirzepatide. Funding Cleveland Clinic - Jack, Joseph and Morton Mandel Accelerator Grants, Grant Number: MAG0030.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $5,780
OpenAlex ID: W7227856628
FWCI:
Cites: 28
Cited by:
Related to: 10